Combined Research

Stock Quotes for Combined Research top ^
  • Industry: Rubber & Plastics
  • Sector: Consumer Cyclical
  • Stock Style: Small Value
Sign-up for n0z investment picks

News Articles for Combined Research top ^
RF Micro Devices, Inc. (Nasdaq: RFMD) and TriQuint Semiconductor, Inc. (Nasdaq: TQNT) announced today that the applicable waiting period under the U.S. Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), in relation to the previously announced business combination between RFMD and TriQuint, expired as of 11:59 p.m. EDT on June 13, 2014, with no action by the Federal Trade Commission or the Department of Justice.
Sign-up for Hart-Scott-Rodino Waiting Period Expires for RFMD and TriQuint Business Combination investment picks
ACE Limited (NYSE: ACE) today reported net income for the quarter ended June 30, 2014, of $2.28 per share, compared with $2.59 per share for the same quarter last year (1) .
Sign-up for ACE Reports Second Quarter Operating Income of $825 Million, up 4.5%, Global P&C Net Premiums up 7% in Constant Dollars; P&C Combined Ratio is 87.5% and Operating Return on Equity is 11.8% investment picks
NEW YORK , July 16, 2014 /PRNewswire/ -- Chart Acquisition Corp.
Sign-up for Chart Acquisition Corp. Agrees To Business Combination With Tempus Jets investment picks
MILWAUKEE, June 30, 2014 (GLOBE NEWSWIRE) -- Jason Industries, Inc., formerly known as Quinpario Acquisition Corp.
Sign-up for Jason Industries, Inc. (Formerly Quinpario Acquisition Corp.) Announces Satisfaction of Business Combination Condition to Warrant Tender Offer investment picks
HOUSTON , June 30, 2014 /PRNewswire/ -- Kraton Performance Polymers, Inc. (NYSE: KRA) today notified Taiwan -based LCY Chemical Corp.
Sign-up for Board of Kraton Performance Polymers, Inc. Notifies LCY Chemical Corp. of Intention to Withdraw Recommendation that Shareholders Approve Agreement to Combine with LCY's Styrenic Block Copolymer Business investment picks
Creates a Leading Diversified Completion and Production Services Provider Greater Scale, Enhanced Service Offerings, Larger Geographic Footprint and Significant Operating Efficiencies Expected to Advance Competitive Positioning and Future Growth Global Alliance with Nabors Supports Acceleration of International Expansion Expected Annual Run-Rate Synergies of More Than $100 Million, Expected to be Fully Realized by 2017 Expected to be Accretive to Cash Earnings Per Share during the First Full Year of Combined Operations HOUSTON , June 25, 2014 /PRNewswire/ -- C&J Energy Services, Inc. (NYSE: CJES) today announced that it has entered into a definitive agreement to merge with Nabors' completion and production businesses to create a leading diversified completion and production services provider.
Sign-up for C&J Energy Services to Combine with Nabors' Completion and Production Businesses in Transaction Valued at $2.86 Billion investment picks
Transaction Highlights: - Creates a leading oilfield services provider with increased critical mass, broader geographic presence and strong international potential - Sharpens Nabors' focus on its drilling businesses, enhances its financial position and maintains emerging upside in completion and production services - Transfers the Nabors' completion and production services businesses in the U.S. and Canada to a combined company with specific focus on these sectors of the market - Delivers nearly $940 million in cash to Nabors and a 53% ownership position in the combined company - The combined entity will be listed on the NYSE as C&J Energy Services Ltd.
Sign-up for Nabors Announces Agreement to Combine its Completion & Production Services Businesses with C&J Energy Services investment picks
Zalicus Inc. (Nasdaq Capital Market: ZLCS) (“Zalicus”), and Epirus Biopharmaceuticals, Inc. (“Epirus”) agreed today that Zalicus stockholders will own 19% of the combined company post-merger.
Sign-up for Zalicus and Epirus Agree Zalicus Stockholders to Own 19% of Combined Company Post-Merger investment picks
Now Targeting $60 Million of Annualized Pre-Tax Cost Savings Fyffes increases its target adjusted EBITA for the full year 2014 from the range €30 to €35 Million to the range €38 to €42 Million Separate Efficiency Initiatives Anticipated to Reduce Chiquita's Costs by approximately $14 to $16 Million CHARLOTTE, N.C. and DUBLIN, Ireland, Aug.
Sign-up for Chiquita and Fyffes Provide Updated Synergy Estimates Related to Proposed Combination investment picks
- Diversifies and Expands Floral and Gift Offerings, Broadens Consumer Reach and Enhances Shopping Experience DOWNERS GROVE, Ill.
Sign-up for FTD Companies, Inc. and Provide Commerce to Combine Businesses Creating a Floral and Gifting Company With Annual Revenue of Over $1 Billion investment picks
Newly-Combined Company Will be Among the Largest Post Acute Care Providers in the Nation Significant Benefits Expected from Scale and Synergies FOOTHILL RANCH, Calif.
Sign-up for Skilled Healthcare To Combine With Genesis HealthCare In 100% Stock Transaction investment picks
Walgreens (NYSE: WAG) (Nasdaq: WAG) today said it has exercised its option to complete the second step of its strategic transaction with Alliance Boots GmbH ahead of the original option period, which was between February and August 2015.
Sign-up for Walgreens Board of Directors Exercises Option to Complete Second Step of Strategic Partnership with Alliance Boots and Fully Combine Both Companies, Creating First Global Pharmacy-Led, Health and Wellbeing Enterprise investment picks
Gilead Sciences, Inc. (Nasdaq:GILD) today announced results from the AMBITION study (a randomized, double-blind, multicenter study of first-line combination therapy with AMB r I sentan and T adalafil in patients with pulmonary arterial hypertens ION ), which was conducted in collaboration with GlaxoSmithKline (GSK). In AMBITION, first-line treatment of pulmonary arterial hypertension (PAH) with the combination of ambrisentan 10 mg and tadalafil 40 mg reduced the risk of clinical failure by 50 percent compared to the pooled ambrisentan and tadalafil monotherapy arm (hazard ratio = 0.502; 95 percent CI: 0.348, 0.724; p=0.0002). The combination was also statistically significant versus the individual ambrisentan and tadalafil monotherapy groups for the primary endpoint (p<0.01). Rates of serious adverse events and events leading to discontinuation were similar across treatment arms.
Sign-up for First-Line Combination of Ambrisentan and Tadalafil Reduces Risk of Clinical Failure Compared to Monotherapy in Pulmonary Arterial Hypertension Outcomes Study investment picks
ST. LOUIS and MILWAUKEE, June 30, 2014 (GLOBE NEWSWIRE) -- Quinpario Acquisition Corp.
Sign-up for Quinpario Acquisition Corp. and Jason Incorporated Announce Closing of Business Combination investment picks
Bristol-Myers Squibb Company (NYSE:BMY) and Celgene Corporation (Nasdaq:CELG) announced today the establishment of a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of a combination regimen of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor, OPDIVO ( nivolumab), and Celgene’s nab ® technology-based chemotherapy ABRAXANE ® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound), in a Phase I study.
Sign-up for Bristol-Myers Squibb and Celgene Enter Clinical Collaboration Agreement to Evaluate Immunotherapy and Chemotherapy Combination Regimen investment picks
BUFFALO, N.Y., Sept.
Sign-up for First Niagara to Combine Consumer Banking Businesses investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar

Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Combined Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Combined Ratio  |  Next: Comerica Bank